key: cord-0697368-k6ag07w7 authors: Dudas, G.; Hong, S. L.; Potter, B. I.; Calvignac-Spencer, S.; Niatou-Singa, F. S.; Tombolomako, T. B.; Fuh-Neba, T.; Vickos, U.; Ulrich, M.; Leendertz, F. H.; Khan, K.; Watts, A.; Olendraite, I.; Snijder, J.; Wijnant, K. N.; Bonvin, A. M.; Martres, P.; Behillil, S.; Ayouba, A.; Maidadi, M. F.; Djomsi, D. M.; Godwe, C.; Butel, C.; Simaitis, A.; Gabrielaite, M.; Katenaite, M.; Norvilas, R.; Raugaite, L.; Jonikas, R.; Nasvytiene, I.; Zemeckiene, Z.; Gecys, D.; Tamusauskaite, K.; Norkiene, M.; Vasiliunaite, E.; Ziogiene, D.; Timinskas, A.; Sukys, M.; Sarauskas, M.; Alzbutas, G.; Juozapaite, D.; Na, title: Travel-driven emergence and spread of SARS-CoV-2 lineage B.1.620 with multiple VOC-like mutations and deletions in Europe date: 2021-05-08 journal: nan DOI: 10.1101/2021.05.04.21256637 sha: 59de56374f9e2992f659ce681de0fa2cf2363dfe doc_id: 697368 cord_uid: k6ag07w7 Many high-income countries have met the SARS-CoV-2 pandemic with overwhelming sequencing resources and have identified numerous distinct lineages, including some with notably altered biology. Over a year into the pandemic following unprecedented reductions in worldwide human mobility, distinct introduced lineages of SARS-CoV-2 without sequenced antecedents are increasingly discovered in high-income countries as a result of ongoing SARS-CoV-2 genomic surveillance initiatives. We here describe one such SARS-CoV-2 lineage, carrying many mutations and deletions in the spike protein shared with widespread variants of concern (VOCs), including E484K, S477N and deletions HV69del, Y144del, and LLA241/243del. This lineage - designated B.1.620 - is known to circulate in Lithuania and has now been found in several European states, but also in increasing numbers in central Africa owing to important recent increases in genome sequencing efforts on the continent. We provide evidence of likely ongoing local transmission of B.1.620 in Lithuania, France, Germany, Spain, Belgium and the Central African Republic. We describe the suite of mutations this lineage carries, its potential to be resistant to neutralising antibodies, travel histories for a subset of the European cases, and evidence of local B.1.620 transmission in Europe. We make a case for the likely Central African origin of this lineage by providing travel records as well as the outcomes of carefully crafted phylogenetic and phylogeographic inference methodologies, the latter of which is able to exploit individual travel histories recorded for infected travellers having entered different European countries. T Only SNPs that differentiate B.1.620 (genomes outlined with a dashed line) from the reference and are shared by at least two B.1.620 genomes are shown in the condensed SNP alignment. Sites identical to the reference (GenBank accession NC 045512) are shown in grey, changes from the reference are indicated and coloured by nucleotide (green for thymidine, red for adenosine, blue for cytosine, yellow for guanine, dark grey for ambiguities, black for gaps). If a mutation results in an amino acid change, the column label indicates the gene, reference amino acid, amino acid site, and amino acid change in brackets. The Bayesian phylogeny (branch lengths number of mutations) on the right shows the relationships between depicted genomes and was rooted on the reference sequence. Posterior probabilities of nodes leading up to lineage B.1.620 are shown near each node. ACE2. The remaining mutations in the spike protein -P681H, T1027I and D1118H -are uncharacterised 206 to the best of our knowledge. Of these, P681H is also located on the outer surface of the spike protein, 207 directly preceding the multibasic S1/S2 furin cleavage site (Hoffmann et al., 2020) . In contrast T1027I 208 and D1118H are both buried in the trimerisation interface of the S2 subunit (Walls et al., 2020) . Figure S4 ). The putative index case for these infections has yet to be determined through 234 contact tracing at the time of writing but these cases clearly point to the B.1.620 lineage circulating 235 in the Val d'Oise department. These infections seem to stem from local ongoing transmission in the 236Î le-de-France region, clustering with two patients ages 1 (sample from a children's hospital in Paris: Hôpital Necker-Enfants malades) and 69. These infections inÎle-de-France in turn cluster with two 238 infections from Le Havre (region of Normandy; 180km from Pontoise), pointing to either a travel event 239 from Normandy toÎle-de-France or possible local transmission in the north of France ( Figure S4 ). In the absence of routine surveillance at a location, sequencing infected travellers originating from 242 there constitutes the next most efficient way to monitor distinct viral populations. This has been used 243 successfully to uncover cryptic outbreaks of Zika virus in Cuba (Grubaugh et al., 2019) and SARS-CoV-2 244 in Iran at the beginning of the pandemic (Lemey et al., 2020). The latter study describes a novel approach 245 to accommodate differences in sampling location and location of infection, and is hence specifically 246 targeted to exploit recorded travel histories of infected individuals in Bayesian phylogeographic inference, 247 rather than arbitrarily assigning the origin of the sample to either location. Of the collected B.1.620 248 genomes in our data set, seven are from travellers returning from Cameroon whereas six were sampled 249 in the Central African Republic (CAR) near the border with Cameroon, indicating the most plausible 250 geographic region where B.1.620 is circulating widely to be Central Africa ( Figure S6) . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 8, 2021. Maximum likelihood tree of lineage B.1.620 in Europe. Relationships between B.1.620 genomes, coloured by country of origin (same as Figure 1 ) with a thicker coloured outline indicating country of origin for travel cases. At least seven genomes shown (samples collected in Belgium, Switzerland, France, and Equatorial Guinea) are from individuals who returned from Cameroon, one is from a traveler returning from Mali and one Lithuanian case returned from France. Genomes from CAR and Czechia (returning traveler from Mali) are descended from the original B.1.620 genotype, while the genome from Equatorial Guinea is already closely related to genomes found in UK and happens to be a travel case from Cameroon. Each genome is connected to available geographic location in Europe with smallest circles indicating municipality-level precision, intermediate size corresponding to county level information (centered on county capital) and largest circle sizes indicating country level information (centered on country capital). Countries are assigned the same colours as in Figures 1 and 3. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Figure 3 . Known locations and travel history of B.1.620 cases. Collection dates of B.1.620 genomes are shown for each country (rows). Genomes from travellers are outlined with colour indicating travel of origin (e.g. red for Cameroon) and connected to a smaller dot indicating which country's diversity is being sampled at travel destination. Bars at the top indicate the number of genomes of B.1.620 available for a given date across all countries. Countries are assigned the same colours as in Figure 1 . Using a Bayesian phylogeographic inference methodology that accommodates individual travel 266 histories we were able to reconstruct location-annotated phylogenies at both the continent and country 267 levels. Figure 4A shows the MCC tree of the continent-level phylogeographic analysis, which yields 268 75% posterior support for an African origin of lineage B.1.620. From this inferred African origin, the 269 variant then spread to different European countries via multiple introductions, which is confirmed by our . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 8, 2021. Total air passenger flows out of Cameroon between 2020 December and 2021 February. Destination countries are coloured by continent, sorted by total number of passengers, and limited to countries where at least 100 passengers have arrived from Cameroon between 2021 December and 2021 February. Numbers above each country's bar indicate the total number of genomes on GISAID from that country since January 1st 2021, according to GISAID's 2021-04-30 metadata release. Bars outlined in black represent countries that have submitted at least one B.1.620 genome as of 2021 May 04. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 8, 2021. ; https://doi.org/10.1101/2021.05.04.21256637 doi: medRxiv preprint In this study we have presented evidence that a SARS-CoV-2 lineage designated B.1.620, first detected 290 in Europe in late February, is associated with Central Africa, where it appears to circulate at very high 291 prevalence, and has been introduced into Europe and the US on multiple occasions. A fair number of 292 known B.1.620 genomes that were sequenced in Europe stem from travel-related cases returning from 293 Cameroon (Figure 3 ), suggesting that it is likely to be the immediate source of this lineage. SARS-CoV-2 294 genomes from CAR from near the border with Cameroon add weight to this hypothesis. So far the only 295 observation that is difficult to explain is the Czech case returning from Mali, since Mali is over 1,000 296 km away from Cameroon. If B.1.620 were to be introduced to Mali via land routes it would first need 297 to rise to high frequency in countries between Central Africa and Mali, at very least Nigeria and Niger. The lack of any B.1.620 genomes from Nigeria to date, despite higher air passenger volumes and active is not routine, is concerning and such occurrences may become an alarming norm. The continued lack of genomic surveillance in multiple areas of the world, let alone equitable access 313 to vaccines to drive transmission down, will continue to undermine efforts to control SARS-CoV-2 314 everywhere. Without the ability to identify unusual variants, to observe their evolution and learn from it, 315 and to evaluate how vaccine-induced immunity protects against them, any response enacted by individual 316 countries is reactive and, much like the process of evolution that generates variants of concern, short-317 sighted. The emergence of B.1.1.7 was unprecedented and has had a devastating impact on the state of 318 the pandemic, so it is concerning that similar information gaps in global genomic surveillance still persist 319 to this day. As an example we have shown that B.1.620 lacks intermediate relatives, resulting in a long 320 branch that connects this lineage to the ancestral genotype of B.1. This could be the result of gradual 321 but unsampled evolution, perhaps even far away from Cameroon and its neighbours, but it could have 322 also happened due to unusual selection pressures in immunosuppressed individuals (Choi et al., 2020) 323 which is hypothesised for lineage B.1.1.7. The long branch leading to B.1.620 also means that we cannot 324 reconstruct the order of mutations that have occurred during the genesis of this lineage and therefore 325 whether some amino acid changes have allowed others to happen by altering the fitness landscape via 326 epistatic interactions (Kemp et al., 2021) . Given the number of VOC-like mutations B.1.620 has, this is a 327 significant loss. Our work highlights that global inequalities, as far as infectious disease monitoring is concerned, have 329 tangible impacts around the world and that until the SARS-CoV-2 pandemic is brought to heel everywhere, 330 nowhere is safe for long. Additionally, we highlight the importance of collecting and sharing associated 331 metadata with genome sequences, in particular regarding individual travel histories, as well as collection 332 dates and locations, all of which are important to perform detailed phylogenetic and phylogeographic 333 analysis. We only observed one single instance where a GISAID entry was accompanied by travel 334 information and had to request such information for all the samples in our core data set by contacting each 335 individual lab. Whereas many labs were quick to provide the requested information, we were certainly . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Table S1 . While we were able to retrieve travel history for a fair number of cases, this information is 388 considered private information in certain countries and we were hence unable to retrieve such data for a 389 subset of our sequences. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 8, 2021. ; https://doi.org/10.1101/2021.05.04.21256637 doi: medRxiv preprint testing (Lauer et al., 2020a), and a standard deviation of 3 days to incorporate the uncertainty on the 447 incubation time. In our phylogeographic analysis, we made use of Bayesian stochastic search variable selection 449 (BSSVS) to simultaneously determine which migration rates are zero depending on the evidence in the 450 data and infer ancestral locations, in addition to providing a Bayes factor test to identify migration rates 451 of significance (Lemey et al., 2009) . We first performed a continent-level phylogeographic analyses by 452 aggregating sampling locations as well as the individual travel histories that occurred between continents. To ensure consistent spatial reconstruction regardless of sampling, we fixed the root location of this tree 454 to be in Asia -so as to match the known epidemiology of the COVID-19 pandemic -and assumed a Table S1 . Individual travel histories collected for the core genomic data set analysed in this study. Importantly, documented travel cases from Cameroon to several European countries were retrieved from the labs that submitted the genomes to GISAID, often with detailed travel dates. Additionally, we were able to retrieve one travel case from Belgium to Lithuania (a truck driver passing through Germany and Poland on the way) through contact tracing, but without the accompanying genome sequence. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 8, 2021. ; Figure S2 . Lithuanian SARS-CoV-2 sequencing programme. Since its inception in February 2021, Lithuania's SARS-CoV-2 sequencing programme has largely sequenced above the European Commission recommended 5% of positive cases. The sequencing programme began at the tail end of the second wave in Lithuania before restrictions were loosened in April 2021. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 8, 2021. ; Figure S3 . Comparison of amino acid mutations present in lineage B.1.620 and VOCs. Each row corresponds to lineage B.1.620 and current variants of concern (VOC) or interest (VOI). Each column is an amino acid change observed in lineage B.1.620 with cells indicating whether the mutation is unique to lineage B.1.620 in this comparison (red), shared with other VOCs/VOIs (blue) or absent (white). Of VOC amino acid changes lineage B.1.620 shares most in common with B.1.1.7 (ORF1a: SGF3675/3677∆, S: Y144∆, S: HV69/70∆, S: P681H, and S: D1118H), followed by P.1 (ORF1a: SGF3675/3677∆, S:P26S, S:E484K, S: T1027I) and B.1.351 (ORF1a: SGF3675/3677∆, S: E484K, S: LLA241/243∆). . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 8, 2021. T N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N T N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N ---N N N N T C N N N N N N N N N N N N ---N N N N N N N N N N N N N N N N N N N N N N N N T T N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N C N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N C G G C C G T C A C T C C C C C C A C C T C A C C C G C C C G G A C G C C C C G C C C C C T C C C C G G C C lineage B.1.620 outlined with a dashed line. Sites identical to the reference (GenBank accession NC 045512) are shown in grey, changes from the reference are indicated and coloured by nucleotide (green for thymidine, red for adenosine, blue for cytosine, yellow for guanine, dark grey for ambiguities, black for gaps). If mutation results in an amino acid change, the column label indicates the gene, reference amino acid, amino acid site, and amino acid change in brackets. Maximum likelihood phylogeny on the right shows the relationships between depicted genomes and was rooted on the reference sequence. Tip circles indicate each genome's country of origin in the same colour scheme as Figures 3 and 2. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 8, 2021. ; https://doi.org/10.1101/2021.05.04.21256637 doi: medRxiv preprint Figure S5 . HADDOCK models of ACE2-RBD interaction. HADDOCK scores and energy terms are listed as average +/-standard error of the cluster. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 8, 2021. ; https://doi.org/10.1101/2021.05.04.21256637 doi: medRxiv preprint Figure S6 . Travel cases and distribution of B.1.620 infections across Africa and Europe. Mali, Cameroon, Central African Republic and Equatorial Guinea are highlighted in Africa and known B.1.620 cases related to travel are displayed as arrows going from known country of origin to destination country. The precise location of B.1.620 cases in Africa is only known for cases from CAR, whose location near the border -near the Dzanga-Sangha Protected Areas -with Cameroon is indicated with a circle. European cases for which no travel information is available and which may represent cases resulting from local transmission are indicated with circles as well. DRC is marked in hatching because B.1.620 from there have been submitted to GISAID, but not used in analyses here. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 8, 2021. ; https://doi.org/10.1101/2021.05.04.21256637 doi: medRxiv preprint ORF1b:P314L) 15324 15346 (ORF1b:L627F) 17110 (ORF1b:A1215S) 17679 17746 (ORF1b:P1427S) 18673 (ORF1b:R1736G) ORF1a:T403I) 1498 1543 1670 (ORF1a:L469F) ORF1a:T951I) 3267 (ORF1a:T1001I) 3620 (ORF1a:G1119S) 3828 (ORF1a:S1188L) 4002 (ORF1a:T1246I) 4055 (ORF1a:H1264Y) ORF1a:R1464W) 4752 (ORF1a:T1496I) 4965 (ORF1a:T1567I) ORF1a:K1655N) 5388 (ORF1a:A1708D) ORF1a:D1939G) 6101 (ORF1a:G1946S) 6183 (ORF1a:K1973R) 6236 (ORF1a:V1991I) 6285 (ORF1a:T2007I) ORF1a:S2024L) 6543 (ORF1a:T2093I) 6578 (ORF1a:L2105F) 6606 (ORF1a:S2114F) ORF1a:A2123V) 6954 (ORF1a:I2230T) ORF1a:A2325V) 7451 (ORF1a:S2396G) 7610 (ORF1a:N2449Y) ORF1a:T2684I) ORF1a:A2850T) ORF1a:F3677-) 11295 (ORF1a:F3677-) 11296 (ORF1a:F3677-) 11417 (ORF1a:V3718F) 11442 (ORF1a:A3726V) 11497 11521 (ORF1a:M3752I) 11596 (ORF1a:Q3777H) 11653 11713 12115 12473 12778 13019 13536 13860 13993 S:D80A) 21846 (S:T95I) 21939 (S:V126A) 21974 (S:D138Y) 21987 (S:G142V) 21991 (S:Y144-) 21992 (S:Y144-) 21993 (S:Y144-) 22020 (S:M153T) 22132 (S:R190S) 22191 (S:I210T) 22205 (S:D215H) 22206 (S:D215G) 22225 22227 (S:A222V) 22259 (S:I233V)